J. Mosquera

发表

Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.

E. Gallardo, P. Jiménez-Fonseca, A. Muñoz, 2022, European journal of internal medicine.

Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors☆

L. A. Antón Aparicio, J. Mosquera, L. León-Mateos, 2015, Redox biology.

Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

A. Concha, L. Calvo, R. Gallego, 2021, Virchows Archiv.

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

B. Massuti, V. Calvo, M. Provencio, 2021, Translational lung cancer research.

Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

A. Navarro, M. Dómine, M. Cobo, 2022, Oncology and Therapy.

Liquid biopsy: the value of different bodily fluids.

N. Cruz-Martins, V. Hespanhol, C. Freitas, 2022, Biomarkers in medicine.

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

N. Girard, S. Novello, B. Besse, 2021, Clinical lung cancer.

10(th) Congress on Lung Cancer-updates on clinical trials: goal.

R. Rosell, B. Massuti, R. Campelo, 2014, Translational lung cancer research.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

D. Planchard, J. Bosch-Barrera, G. Zalcman, 2022, European journal of cancer.

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

I. Gich, A. Barnadas, R. García-Campelo, 2020, Frontiers in Oncology.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal for ImmunoTherapy of Cancer.

Risk factors for positive margins in conservative surgery for breast cancer after neoadjuvant chemotherapy.

B. Acea, A. Iglesias, J. Mosquera, 2016, Cirugia espanola.

Evaluation of MRI Accuracy After Primary Systemic Therapy in Breast Cancer Patients Considering Tumor Biology: Optimizing the Surgical Planning

B. Acea, A. Iglesias, J. Mosquera, 2019, Radiology and oncology.

Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients

L. Calvo, T. Seoane-Pillado, B. Acea, 2016, Radiology and oncology.

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

A. Concha, L. Calvo, S. Antolín, 2018, Breast cancer.

Lung cancer patients with COVID-19 in Spain: GRAVID study

M. Provencio, E. Nadal, M. Dómine, 2021, Lung Cancer.

OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases

E. Felip, M. Simó, J. Bruna, 2021, Journal of Thoracic Oncology.

Immunogenicity of COVID-19 vaccines in lung cancer patients.

J. Bosch-Barrera, V. Calvo, M. Provencio, 2023, Lung cancer.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Javier M. Martín-López, J. Bosch-Barrera, N. Reguart, 2023, New England Journal of Medicine.